First U.S. Case Performed With Endosense’s TactiCath® Quartz Contact-Force Sensing Ablation Catheter

Published: Feb 01, 2013

GENEVA--(BUSINESS WIRE)--Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its new generation TactiCath Quartz contact-force sensing ablation catheter has been used for the first time in the United States by Dr. J. Michael Mangrum at University of Virginia Medical Center in Charlottesville, Va. The first U.S. case was performed on January 31 as part of an amended protocol of the company’s TOCCASTAR investigational device exemption (IDE) clinical study of the TactiCath (called the "TOCCASTAR Supplemental Clinical Study"). The supplemental study’s protocol is identical to that of original TOCCASTAR study, with the exception that the patients treated with the newer device will not be randomized.

Back to news